Twist Bioscience Corp. Hits New 52-Week High of $70.99

Twist Bioscience Corp. has achieved a significant milestone by reaching a new 52-week high of USD 70.99 on May 29, 2026. This notable performance reflects a robust increase of 33.71% over the past year, outperforming the S&P 500, which recorded a gain of 28.21% during the same period. As a small-cap company in the Pharmaceuticals & Biotechnology sector, Twist Bioscience boasts a market capitalization of USD 2,760 million. Despite its recent price surge, the company remains in a loss-making position, with a negative return on equity of -16.79%. The stock's price-to-book ratio stands at 6.05, indicating a premium valuation relative to its book value. Twist Bioscience's financial metrics also reveal a debt-to-equity ratio of -0.41, suggesting a unique capital structure. The company does not offer a dividend yield, which is typical for firms in its growth phase. The stock's previous 52-week low was recorded at USD 23.50, highlighting the significant upward trajectory it has experienced in recent months.